Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis

被引:4
作者
Tian-Wei Qian [1 ,2 ]
Meng-Ya Zhao [1 ,2 ]
Xin-Xin Li [1 ,2 ]
Xun Xu [1 ,2 ]
机构
[1] Department of Ophthalmology,Shanghai General Hospital
[2] Shanghai Key Laboratory of Ocular Fundus Diseases
基金
中国国家自然科学基金;
关键词
ranibizumab; diabetic macular edema; laser therapy; anti-vascular endothelial growth factor; Meta-analysis;
D O I
暂无
中图分类号
R587.2 [糖尿病性昏迷及其他并发症]; R774.5 [黄斑、中心窝疾病];
学科分类号
1002 ; 100201 ; 100212 ;
摘要
AIM: To compare the therapeutic effect and safety of laser photocoagulation along with intravitreal ranibizumab(IVR) versus laser therapy in treatment of diabetic macular edema(DME).METHODS: Pertinent publications were identified through comprehensive searches of Pub Med, EMBASE, Web of Science, Cochrane Library, and Clinical Trials.gov to identify randomized clinical trials(RCTs) comparing IVR+laser to laser monotherapy in patients with DME. Therapeutic effect estimates were determined by weighted mean differences(WMD) of change from baseline in best corrected visual acuity(BCVA) and central retinal thickness(CRT) at 6, 12, or 24 mo after initial treatment, and the risk ratios(RR) for the proportions of patients with at least 10 letters of improvement or reduction at 12 mo. Data regarding major ocular and nonocular adverse events(AEs) were collected and analyzed. The Review Manager 5.3.5 was used.RESULTS: Six RCTs involving 2069 patients with DME were selected for this Meta-analysis. The results showed that IVR+laser significantly improved BCVA compared with laser at 6mo(WMD: 6.57; 95% CI: 4.37-8.77; P<0.00001), 12mo(WMD: 5.46; 95% CI: 4.35-6.58; P<0.00001), and 24mo(WMD: 3.42; 95% CI: 0.84-5.99; P=0.009) in patients with DME. IVR+laser was superior to laser in reducing CRT at 12 mo from baseline with statistical significance(WMD:-63.46; 95% CI:-101.19 to-25.73; P=0.001). The pooled RR results showed that the proportions of patients with at least 10 letters of improvement or reduction were in favor of IVR+laser arms compared with laser(RR: 2.13; 95% CI: 1.77-2.57; P<0.00001 and RR: 0.37; 95% CI: 0.22-0.62; P=0.0002, respectively). As for AEs, the pooled results showed that a significantly higher proportion ofpatients suffering from conjunctival hemorrhage(study eye) and diabetic retinal edema(fellow eye) in IVR+laser group compared to laser group(RR: 3.29; 95% CI: 1.53-7.09; P=0.002 and RR: 3.02; 95% CI: 1.24-7.32; P=0.01, respectively). The incidence of other ocular and nonocular AEs considered in this Meta-analysis had no statistical difference between IVR+laser and laser alone.CONCLUSION: The results of our analysis show that IVR+laser has better availability in functional(improving BCVA) and anatomic(reducing CRT) outcomes than laser monotherapy for the treatment of DME. However, the patients who received the treatment of IVR+laser may get a higher risk of suffering from conjunctival hemorrhage(study eye) and diabetic retinal edema(fellow eye).
引用
收藏
页码:1134 / 1143
页数:10
相关论文
共 21 条
[1]   Macular laser photocoagulation with or without intravitreal triamcinolone pretreatment for diabetic macular edema: a result from five randomized controlled trials [J].
Xiang-Dong Liu ;
Xiao-Dong Zhou ;
Zhi Wang ;
Yong-Ming Shen .
International Journal of Ophthalmology, 2016, (01) :132-138
[2]  
Comments on Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials[J] . Takkar Brijesh,Azad Shorya.Ophthalmology . 2015
[3]  
A Multimodal Approach to Diabetic Macular Edema[J] . Adrian Au,Rishi P. Singh.Journal of Diabetes and Its Complications . 2015
[4]  
Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME[J] . Alan Berger,Tom Sheidow,Alan F. Cruess,Jean Daniel Arbour,Anne-Sophie Courseau,Frederica de Takacsy.Canadian Journal of Ophthalmology/Journal canadie . 2015 (3)
[5]  
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results[J] . Michael J. Elman,Allison Ayala,Neil M. Bressler,David Browning,Christina J. Flaxel,Adam R. Glassman,Lee M. Jampol,Thomas W. Stone.Ophthalmology . 2014
[6]  
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment[J] . Michael J. Elman,Haijing Qin,Lloyd Paul Aiello,Roy W. Beck,Neil M. Bressler,Frederick L. Ferris,Adam R. Glassman,Raj K. Maturi,Michele Melia.Ophthalmology . 2012 (11)
[7]   Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration [J].
Costagliola, Ciro ;
Agnifili, Luca ;
Arcidiacono, Barbara ;
Duse, Sarah ;
Fasanella, Vincenzo ;
Mastropasqua, Rodolfo ;
Verolino, Marco ;
Semeraro, Francesco .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (10) :1299-1313
[8]  
Intravitreal Ranibizumab (Lucentis) for the Treatment of Diabetic Macular Edema: A Systematic Review and Meta-Analysis of Randomized Clinical Control Trials[J] . Haiyan Wang,Xiaodong Sun,Kun Liu,Xun Xu.Current Eye Research . 2012 (8)
[9]  
Ranibizumab for Diabetic Macular Edema[J] . Quan Dong Nguyen,David M. Brown,Dennis M. Marcus,David S. Boyer,Sunil Patel,Leonard Feiner,Andrea Gibson,Judy Sy,Amy Chen Rundle,J. Jill Hopkins,Roman G. Rubio,Jason S. Ehrlich.Ophthalmology . 2012 (4)
[10]   Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema [J].
Ozturk, Banu Turgut ;
Kerimoglu, Hurkan ;
Adam, Mehmet ;
Gunduz, Kemal ;
Okudan, Suleyman .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2011, 25 (05) :298-302